Targeted Therapy of Melanoma
Berking C (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 19
Pages Range: S86-
Journal Issue: 2
DOI: 10.1016/j.jisp.2018.09.009
Abstract
In recent years, the treatment of advanced melanoma has been revolutionized by the introduction of new innovative approaches, namely mutation-based targeted therapy and immune checkpoint blockade by CTLA4 and PD-1/PD-L1 inhibitors. The decade-long era of chemotherapy with very low response rates of 5–20% and short median survival rates of 6–9 months has been left in favor of new therapies with response rates ranging between 40% and 70% and median overall survival rates of 2 years and longer (Heppt et al., 2015, Larkin et al., 2014, Long et al., 2015, Long et al., 2016, Schadendorf et al., 2015).
Involved external institutions
Germany (DE)How to cite
APA:
Berking, C. (2018). Targeted Therapy of Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 19(2), S86-. https://doi.org/10.1016/j.jisp.2018.09.009
MLA:
Berking, Carola. "Targeted Therapy of Melanoma." Journal of Investigative Dermatology Symposium Proceedings 19.2 (2018): S86-.
BibTeX: Download